natgillin/translations-raw huggingface dataset:
This is because Bondronat can affect the way some other medicines work. 
Zdravilo Bondronat lahko vpliva na delovanje drugih zdravil.
Then you can have your first food and drink, and take any medicines or supplements 
Nato lahko zaužijete prvo hrano, pijačo in druga zdravila ali dodatke.
Nevertheless, according to clinical assessment of the individual patient, it is recommended that renal function, serum calcium, phosphate and magnesium should be monitored in patients treated with Bondronat. 
Glede na klinično oceno posameznega bolnika pa je ledvično funkcijo, serumske koncentracije kalcija, fosfata in magnezija pri bolnikih, ki se zdravijo z zdravilom Bondronat, priporočljivo spremljati.
Receiving this medicine 
Prejemanje zdravila
All Skeletal Related Events (SREs) Placebo n=277 
vsi z okostjem povezani dogodki (SREs) Placebo n = 277
• skin problems 
• kožne težave,
The median time to relapse was 26 days with a dose of 6 mg. 
Mediana časa do relapsa je pri odmerku 6 mg znašala 26 dni.
Paediatric population (see section 4.2 and section 5.2) The safety and efficacy of Bondronat in children and adolescents below the age of 18 years have not been established. 
Pediatrična populacija (glejte poglavji 4.2 in 5.2) Varnost in učinkovitost zdravila Bondronat pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
≥50 CLcr<80 6 mg (6 ml of concentrate for solution for infusion) 
≥50 CLcr < 80 6 mg (6 ml koncentrata za raztopino za infundiranje)
Injury, poisoning and procedural complications 
Poškodbe in zastrupitve in zapleti pri posegih poškodba,
• sleep problems, feeling anxious, emotional instability, or mood swings 
• težave s spanjem, občutek zaskrbljenosti, čustvena nestabilnost ali menjava razpoloženja,
The recommended dose is one 50 mg film-coated tablet daily. 
Odmerjanje Priporočeni odmerek je ena 50 mg filmsko obložena tableta na dan.
While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Bondronat administration. 
Invazivne zobozdravstvene posege se lahko med zdravljenjem opravi le po temeljitem razmisleku, zlasti se jim je treba izogibati v času blizu termina prejema zdravila Bondronat.
METHOD AND ROUTE(S) OF ADMINISTRATION Do not suck, chew or crush tablets Read the package leaflet before use Oral use 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Tablet ne sesajte, žvečite ali drobite Pred uporabo preberite priloženo navodilo Peroralna uporaba
• if you have high or low blood levels of vitamin D or any other minerals 
• če imate visoke ali nizke koncentracije vitamina D ali drugih mineralov v krvi,
If you forget to take Bondronat 
Če ste pozabili vzeti zdravilo Bondronat
Also some other medicines can affect the way Bondronat works. 
Prav tako lahko druga zdravila vplivajo na delovanje zdravila Bondronat.
Clinical studies have not shown any evidence of deterioration in renal function with long term Bondronat therapy. 
Klinične študije niso pokazale, da bi pri dolgotrajnem zdravljenju z zdravilom Bondronat prišlo do poslabšanja ledvične funkcije.
Dosage: Treatment of Tumour-induced Hypercalcaemia Bondronat is usually administered in a hospital setting. 
Odmerjanje: zdravljenje tumorsko povzročene hiperkalciemije Dajanje zdravila Bondronat običajno poteka v bolnišnici.
What Bondronat looks like and contents of the pack Bondronat is a colourless, clear solution. 
Izgled zdravila Bondronat in vsebina pakiranja Zdravilo Bondronat je brezbarvna, bistra raztopina.
Bondronat should not be used during breast-feeding. 
Zdravila Bondronat se ne sme uporabljati med dojenjem.
• weakness 
• šibkost.
As no clinical data are available, dose recommendations cannot be given for patients with severe hepatic insufficiency (see section 4.2). 
Ker za bolnike s težko insuficienco jeter klinični podatki niso na voljo, za to skupino bolnikov ne moremo dati priporočil o odmerjanju (glejte poglavje 4.2).
Milk or antacids should be given to bind Bondronat. 
Za vezavo zdravila Bondronat je treba zaužiti mleko ali antacide.
Sodium acetate, sodium chloride, acetic acid and water for injections. 
Natrijev acetat, natrijev klorid, ocetna kislina in voda za injekcije.
Female patients with breast cancer and radiologically confirmed bone metastases were randomised to receive placebo (158 patients) or 6 mg Bondronat (154 patients). 
Bolnice z rakom dojke in radiološko potrjenimi metastazami v kosteh so prejemale placebo (158 bolnic) ali 6 mg zdravila Bondronat (154 bolnic).
Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR United Kingdom 
Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR Velika Britanija
• a condition affecting the blood vessels in your brain called ‘cerebrovascular disorder' (stroke or brain bleeding) 
• stanje, ki prizadene žile v možganih, imenovano cerebrovaskularna bolezen (kap ali krvavitev iz možganov),
Contains 88.1 mg lactose (as lactose monohydrate). 
Pomožne snovi z znanim učinkom: vsebuje 88,1 mg laktoze (v obliki laktoze monohidrata).
Care must be taken not to administer Bondronat concentrate for solution for infusion via intra-arterial or paravenous administration, as this could lead to tissue damage. 
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Bondronat ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
• Stay upright (sitting or standing) while taking your tablet and for the next hour (60 minutes). 
• med jemanjem tablete in še naslednjo uro (60 minut) ostanete v pokončnem položaju (stoje ali sede).
Female patients with breast cancer and radiologically confirmed bone metastases were randomised to receive placebo (277 patients) or 50 mg Bondronat (287 patients). 
Bolnice z rakom dojke in radiološko potrjenimi metastazami v kosteh so prejemale placebo (277 bolnic) ali 50 mg zdravila Bondronat (278 bolnic).
Urinary concentrations of the bone resorption marker CTx (C-terminal telopeptide released from Type I collagen) were significantly reduced in the Bondronat group compared to placebo. 
Koncentracije označevalca resorpcije kosti CTx (C-terminalni telopeptid, ki se sprosti s kolagena tipa I) v seču so bile v skupini zdravljeni z zdravilom Bondronat v primerjavi s placebom značilno znižane.
• stomach problems such as ‘gastroenteritis” or ‘gastritis' 
• težave z želodcem, kot sta gastroenteritis in gastritis,
Manufacturer Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR United Kingdom 
Izdelovalec Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR Velika Britanija
• tablet core: lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, purified stearic acid, colloidal anhydrous silica 
• jedro tablete: monohidrat laktoze, povidon, mikrokristalna celuloza, krospovidon, prečiščena stearinska kislina, brezvoden koloidni silicijev dioksid;
On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that Bondronat has no or negligible influence on the ability to drive and use machines. 
Glede na farmakodinamske in farmakokinetične lastnosti ter poročane neželene učinke pričakujemo, da zdravilo Bondronat nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
There was also a 38% reduction in the risk of developing an SRE for Bondronat treated patients when compared with placebo (relative risk 0.62, p=0.003). 
V primerjavi s placebom je bilo tveganje za nastanek SRE pri bolnikih, zdravljenih z zdravilom Bondronat, za 38 % manjše (relativno tveganje 0,62, p = 0,003).
- Hypersensitivity to ibandronic acid or to any of the excipients listed in section 6.1. 
- Preobčutljivost na ibandronsko kislino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Subjects with severe renal impairment (CLcr  30 mL/min) receiving oral administration of 10 mg ibandronic acid daily for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function (CLcr ≥80 mL/min). 
Bolniki s hudo motnjo ledvičnega delovanja (CLcr  30 ml/min), ki so peroralno prejemali 10 mg ibandronske kisline na dan 21 dni, so imeli 2 do 3-krat višje plazemske koncentracije kot osebe z normalno ledvično funkcijo (CLcr ≥ 80 ml/min).
Paediatric population (see section 4.2 and section 5.1) There are no data on the use of Bondronat in patients less than 18 years old. 
Pediatrična populacija (glejte poglavji 4.2 in 5.1) O uporabi zdravila Bondronat pri bolnikih, mlajših od 18 let, ni podatkov.
• itching, swelling of your face, lips, tongue and throat with difficulty breathing. 
• srbenje, otekanje obraza, ustnic, jezika in žrela s težkim dihanjem.
• if you have problems with your food pipe/gullet (oesophagus) such as narrowing or difficulty swallowing 
• če imate težave s požiralnikom (ezofagusom), kot so zoženje ali težave s požiranjem,
Appropriate medical support and monitoring measures should be readily available when Bondronat intravenous injection is administered. 
Pri dajanju intravenske injekcije zdravila Bondronat mora biti na voljo ustrezna medicinska podpora in nadzor.
How much to receive 
Koliko zdravila morate prejeti
Common (may affect up to 1 in 10 people): feeling sick, heartburn and discomfort in swallowing (inflammation of your gullet/ food pipe) 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): • slabost, zgaga ali neugodje pri požiranju (vnetje požiralnika).
Table 1 lists adverse drug reactions from the pivotal phase III studies (Treatment of tumour induced hypercalcaemia: 311 patients treated with Bondronat 2 mg or 4 mg; Prevention of skeletal events in patients with breast cancer and bone metastases: 152 patients treated with Bondronat 6 mg), and from post-marketing experience. 
Preglednica 1 prikazuje neželene učinke iz ključne študije faze III (zdravljenje tumorsko povzročene hiperkalciemije: 311 bolnikov se je zdravilo z zdravilom Bondronat 2 mg ali 4 mg; preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh: 152 bolnikov se je zdravilo z zdravilom Bondronat 6 mg) in iz obdobja po prihodu zdravila na trg.
What you need to know before you receive Bondronat 
Kaj morate vedeti, preden boste prejeli zdravilo Bondronat
• aching joints, arthritis, or other joint problems 
• bolečine v sklepih, artritis ali druge težave s sklepi,
Bondronat therapy should only be initiated by physicians experienced in the treatment of cancer. 
Zdravljenje z zdravilom Bondronat lahko začnejo le zdravniki, ki imajo izkušnje z zdravljenjem raka.
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those expected for this class of medicinal products (bisphosphonates). 
Neželeni učinki ibandronske kisline v študijah vplivov na sposobnost za razmnoževanje pri podganah so bili pričakovano značilni za to skupino zdravil (difosfonati).
• tooth problems 
• težave z zobmi.
Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Bondronat is given to patients with active upper gastrointestinal problems (e.g. known Barrett's oesophagus, dysphagia, other oesophageal diseases, gastritis, duodenitis or ulcers). 
Zaradi možnega draženja in poslabšanja osnovne bolezni je pri dajanju zdravila Bondronat bolnikom z aktivnimi težavami v zgornjem delu prebavne cevi (npr. Barrettov požiralnik, disfagija, druge bolezni ezofagusa, gastritis, duodenitis ali razjede) potrebna previdnost.
You may have early signs of a possible unusual fracture of the thigh bone 
To so lahko zgodnji znaki možnega netipičnega zloma stegnenice.
There is no evidence for clinically relevant interethnic differences between Asians and Caucasians in ibandronic acid disposition. 
Za klinično pomembne medetnične razlike v biološki uporabnosti ibandronske kisline med Azijci in Kavkazijci ni dokazov.
If you have a raised calcium level in your blood due to a tumour,then the recommended dose is a single administration of 2 mg or 4 mg depending on the severity of your illness. 
Če imate zvišano koncentracijo kalcija v krvi zaradi tumorja, je priporočeni odmerek 2 mg ali 4 mg v enkratnem odmerku, odvisno od resnosti bolezni.
For treatment of tumour induced hypercalcaemia, Bondronat concentrate for solution for infusion is generally given as a single infusion. 
Za zdravljenje tumorsko povzročene hiperkalciemije običajno dajemo koncentrat za raztopino za infundiranje Bondronat kot enkratno infuzijo.
• a high level of alkaline phosphatase in your blood 
• visoka koncentracija alkalne fosfataze v krvi,
Your doctor will work out how much Bondronat you will be given depending on your illness. 
Glede na vašo bolezen bo vaš zdravnik določil, kolikšen odmerek zdravila Bondronat boste prejeli.
Patients with known hypersensitivity to other bisphosphonates Caution is to be taken in patients with known hypersensitivity to other bisphosphonates. 
Bolniki z znano preobčutljivostjo na druge difosfonate Previdnost je potrebna pri bolnikih z znano preobčutljivostjo na druge difosfonate.
Method of administration For intravenous administration. 
Način uporabe Za intravensko uporabo.
• a skin growth called a ‘benign skin neoplasm” 
• rast kože, imenovana benigna neoplazma kože,
Prior to treatment with Bondronat the patient should be adequately rehydrated with 9 mg/ml (0.9%) sodium chloride solution. 
Pred začetkom zdravljenja z zdravilom Bondronat je potrebna zadostna rehidracija bolnika z natrijevim kloridom 9 mg/ml (0,9 %).
Bondronat concentrate for solution for infusion should be administered as an intravenous infusion over 2 hours. 
Zdravilo Bondronat koncentrat za raztopino za infundiranje je treba aplicirati v obliki intravenske infuzije 2 uri.
Patients treated with Bondronat should be given the package leaflet and the patient reminder card. 
Bolnikom, ki prejemajo zdravilo Bondronat, je treba izročiti navodilo za uporabo in opozorilno kartico za bolnika.
In the dose range recommended for treatment, the following response rates with the respective confidence intervals have been shown in clinical trials for patients with baseline albumin-corrected serum calcium  3.0 mmol/l after adequate rehydration. 
V razponih odmerkov, priporočenih za zdravljenje, so med kliničnimi preskušanji za bolnike, ki so pred začetkom zdravljenja imeli korigirani kalcij v serumu  3,0 mmol/l po ustrezni rehidraciji, ugotovili naslednje hitrosti odziva in intervale zaupanja.
Clinical studies in the treatment of tumour-induced hypercalcaemia Clinical studies in hypercalcaemia of malignancy demonstrated that the inhibitory effect of ibandronic acid on tumour-induced osteolysis, and specifically on tumour-induced hypercalcaemia, is characterised by a decrease in serum calcium and urinary calcium excretion. 
Klinične študije zdravljenja tumorsko povzročene hiperkalciemije Klinične študije hiperkalciemije zaradi malignosti so pokazala, da je za zaviralni učinek ibandronske kisline na tumorsko povzročeno osteolizo in še posebno na hiperkalciemijo, povzročeno s tumorjem, značilno znižanje serumskega kalcija in zmanjšano izločanje kalcija z urinom.
This was a composite endpoint which had the following skeletal related events (SREs) as sub-components: 
Cilj raziskave je sestavljalo več, z okostjem povezanih, dogodkov (SRE - skeletal related event):
- Patients should not lie down for 60 minutes after taking Bondronat. 
- Po zaužitju zdravila Bondronat bolniki 60 minut ne smejo leči.
Hypersensitivity†, bronchospasm†, angioedema†, Anaphylactic reaction/shock†** 
Bolezni imunskega sistema preobčutljivost†, bronhospazem†, angioedem†, anafilaktična reakcija/šok†**
• a heart rhythm problem called ‘bundle branch block' 
• težava s srčnim ritmom, imenovana kračni blok,
If you have a raised calcium level in your blood due to a tumour then the recommended dose is a single administration of 1 vial (2 mg) or 2 vials (4 mg), depending on the severity of your illness. 
Če imate zvišano koncentracijo kalcija v krvi zaradi tumorja, je priporočeni odmerek 1 viala (2 mg) ali 2 viali (4 mg) v enkratnem odmerku, odvisno od resnosti bolezni.
Bondronat is indicated in adults for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. 
Bondronat je indiciran pri odraslih za preprečevanje z okostjem povezanih dogodkov (patološke frakture; zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh.
- Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases 
- preprečevanje z okostjem povezanih dogodkov (patološke frakture, zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh;
No specific information is available on the treatment of overdosage with Bondronat. 
Za ravnanje pri prevelikem odmerjanju z zdravilom Bondronat ni posebnih priporočil.
Sleep disorder, anxiety, affection lability 
Psihiatrične motnje motnje spanca, anksioznost, čustvena labilnost
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Bondronat. 
Vsem bolnikom je treba naročiti, naj med zdravljenjem z zdravilom Bondronat skrbijo za dobro ustno higieno in redno opravljajo preglede pri zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečina, oteklina, slabo celjenje ali izcedek iz ran, pa naj takoj obvestijo zdravnika.
The following risk factors should be considered when evaluating a patient's risk of developing ONJ: - Potency of the medicinal product that inhibit bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy - Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking - Concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck - Poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, invasive dental procedures e.g. tooth extractions 
pot uporabe (večje tveganje pri parenteralni uporabi) in kumulativni odmerek zdravila, ki zavira resorpcijo kosti; - sočasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe), kajenje; - sočasno zdravljenje: kortikosteroidi, kemoterapija, zaviralci angiogeneze, obsevanje glave in vratu; - slaba ustna higiena, parodontalna bolezen, slabo prileganje proteze, zobozdravstvene bolezni v anamnezi, invazivni zobozdravstveni poseg, npr. izdrtje zoba.
• The other ingredients are sodium chloride, acetic acid, sodium acetate and water for injections 
• Pomožne snovi so natrijev klorid, ocetna kislina, natrijev acetat in voda za injekcije.
If you have breast cancer that has spread to your bones, then the recommended dose is 3 vials (6 mg) every 3-4 weeks, as an infusion in your vein over at least 15 minutes. 
Če imate raka dojke, ki se je razširil na kosti, je priporočeni odmerek 3 viale (6 mg) vsake 3-4 tedne, kot vsaj 15-minutna infuzija v veno.
Table 1 lists adverse reactions from 2 pivotal phase III studies (Prevention of skeletal events in patients with breast cancer and bone metastases: 286 patients treated with Bondronat 50 mg administered orally), and from post-marketing experience. 
Preglednica 1 prikazuje neželene učinke iz dveh ključnih študij faze III (preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh: 286 bolnikov se je zdravilo z zdravilom Bondronat 50 mg, dajanim peroralno) in iz obdobja po prihodu zdravila na trg.
Medicinal products and supplements (including calcium) should similarly be avoided prior to taking Bondronat tablets. 
Pred jemanjem tablet Bondronat se je prav tako treba izogibati jemanjem drugih zdravil in dodatkov (vključno s kalcijem).
What Bondronat is and what it is used for What you need to know before you receive Bondronat How to receive Bondronat 
Kaj je zdravilo Bondronat in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Bondronat Kako boste prejeli zdravilo Bondronat Možni neželeni učinki
Nevertheless, according to clinical assessment of the individual patient, it is recommended that renal function, serum calcium, phosphate and magnesium should be monitored in patients treated with Bondronat (see section 4.2). 
Vseeno pa je glede na klinično oceno posameznega bolnika pri zdravljenju z zdravilom Bondronat priporočljivo spremljati delovanje ledvic, serumski kalcij, fosfat in magnezij (glejte poglavje 4.2).
Mutagenicity/Carcinogenicity: 
Mutagenost in kancerogeni potencial:
This is because NSAIDs, and Bondronat can both irritate your stomach and gut 
NSAID in zdravilo Bondronat lahko dražijo želodec in črevo;
• low calcium or phosphate levels in your blood 
• nizka koncentracija kalcija ali fosfatov v krvi,
EU/1/96/012/012: 5 vials 
EU/1/96/012/012: 5 vial
Do not receive this medicine if any of the above apply to you. 
Če se kar koli od zgoraj naštetega nanaša na vas, tega zdravila ne smete prejeti.
EU/1/96/012/013: 10 vials 
EU/1/96/012/013: 10 vial
Bondronat is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases'). 
Zdravilo Bondronat uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
• low calcium levels in your blood 
• nizke koncentracije kalcija v krvi,
Patients with cardiac impairment Overhydration should be avoided in patients at risk of cardiac failure. 
Bolniki z okvaro srca Pri bolnikih z nevarnostjo srčnega popuščanja se je treba izogibati hiperhidraciji.
In order to avoid potential incompatibilities, Bondronat concentrate for solution for infusion should only be mixed with isotonic sodium chloride solution or with 5% dextrose solution. 
Da bi se izognili možnim inkompatibilnostim, lahko koncentrat za raztopino za infundiranje Bondronat razredčimo le z izotonično raztopino natrijevega klorida ali 5-% raztopino glukoze.
Excipients with known effect Bondronat is essentially sodium free. 
Pomožne snovi z znanim učinkom Zdravilo Bondronat je praktično brez natrija.
Table 1 Adverse Drug Reactions Reported for Oral Administration of Bondronat System Organ 
Neželeni učinki, o katerih so poročali pri peroralnem dajanju zdravila Bondronat Organski sistem
If you have breast cancer that has spread to your bones, then the recommended dose is 1 vial (6 mg) every 3-4 weeks, as an infusion in your vein over at least 15 minutes. 
Če imate raka dojke, ki se je razširil na kosti, je priporočeni odmerek 1 viala (6 mg) vsake 3-4 tedne, kot vsaj 15-minutna infuzija v veno.
• mouth ulcers, swollen lips (‘cheilitis'), oral thrush 
• ustne razjede, otekle ustnice (heilitis), ustni oprh,
What Bondronat looks like and contents of the pack The film-coated tablets are of oblong shape and white to off-white in colour, engraved L2/IT. 
Filmsko obložene tablete so podolgovate oblike in bele do sivo bele barve z oznako L2/IT.
NAME OF THE MARKETING AUTHORISATION HOLDER Atnahs Pharma Netherlands B.V. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Atnahs Pharma Netherlands B.V.
- radiotherapy to bone for treatment of fractures/impending fractures - surgery to bone for treatment of fractures - vertebral fractures - non-vertebral fractures 
- zdravljenje kosti z obsevanjem zaradi fraktur/pretečih fraktur, - operacija kosti za zdravljenje fraktur, - vertebralne frakture, - nevertebralne frakture.
• fluid in your lungs 
• nabiranje tekočine v pljučih,
Paraesthesia, dysgeusia (taste perversion) 
Bolezni živčevja parestezija, disgevzija (motnje čuta za okus)
This is because aminoglycosides and Bondronat can both lower the amount of calcium in your blood. 
Aminoglikozidi in zdravilo Bondronat lahko znižajo koncentracijo kalcija v krvi.
Bondronat should not be mixed with calcium containing solutions. 
Zdravila Bondronat ne smemo mešati z drugimi raztopinami, ki vsebujejo kalcij.
Bondronat contains the active substance ibandronic acid. 
Zdravilo Bondronat vsebuje zdravilno učinkovino ibandronsko kislino.